m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00339)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
MTOR
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Methyltransferase-like 3 (METTL3) [WRITER]
Representative RNA-seq result indicating the expression of this target gene regulated by METTL3 | ||
Cell Line | Liver | Mus musculus |
Treatment: Mettl3 knockout liver
Control: Wild type liver cells
|
GSE198512 | |
Regulation |
|
logFC: 8.34E-01 p-value: 1.58E-02 |
More Results | Click to View More RNA-seq Results | |
Representative RIP-seq result supporting the interaction between MTOR and the regulator | ||
Cell Line | MDA-MB-231 | Homo sapiens |
Regulation | logFC: 1.47E+00 | GSE60213 |
In total 4 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | METTL3-mediated m6 A methylation promotes lung cancer progression via activating PI3K/AKT/Serine/threonine-protein kinase mTOR (MTOR) pathway. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Lung cancer | ICD-11: 2C25 | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
PI3K-Akt signaling pathway | hsa04151 | |||
In-vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens | CVCL_0023 |
In-vivo Model | 5 × 106 A549 cells overexpressing METTL3 (Lv-METTL3) or control (Lv-Ctrl) were suspended in 100?uL phosphate-buffered saline (PBS), and were subcutaneously injected into mouse lower right flank. Drug treatment started in the Lv-METTL3 group when the tumour volume reached around 100 mm3. Mice were randomly divided into three groups to receive vehicle, GSK2536771 (30 mg/kg) or rapamycin (1 mg/kg). Drugs were administrated daily through intraperitoneal injection for 18 days. Treatment conditions were chosen as previously reported. | |||
Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene | [2] | |||
Response Summary | Knockdown of METTL3 could obviously promote cell proliferation, migration and invasion function, and induce G0/G1 arrest,METTL3 acts as a novel marker for tumorigenesis, development and survival of RCC. Knockdown of METTL3 promoted changes in pI3K/AKT/Serine/threonine-protein kinase mTOR (MTOR) markers' expression with a gain in p-PI3k, p-AKT, p-mTOR and p-p70, and a loss of p-4EBP1. | |||
Target Regulation | Down regulation | |||
Responsed Disease | Renal cell carcinoma | ICD-11: 2C90 | ||
Cell Process | Epithelial-to-mesenchymal transition | |||
Arrest cell cycle at G0/G1 phase | ||||
In-vitro Model | ACHN | Papillary renal cell carcinoma | Homo sapiens | CVCL_1067 |
Caki-1 | Clear cell renal cell carcinoma | Homo sapiens | CVCL_0234 | |
Caki-2 | Papillary renal cell carcinoma | Homo sapiens | CVCL_0235 | |
HK2 | Normal | Acipenser baerii | CVCL_YE28 | |
In-vivo Model | Cells (5×106 cells in 200 uL) were suspended with 100 uL PBS and 100 uL Matrigel Matrix, and injected subcutaneously into the left armpit of each mouse. | |||
Experiment 3 Reporting the m6A Methylation Regulator of This Target Gene | [3] | |||
Response Summary | METTL3 promotes the progression of retinoblastoma through PI3K/AKT/Serine/threonine-protein kinase mTOR (MTOR) pathways in vitro and in vivo. METTL3 has an impact on the PI3K-AKT-mTOR-P70S6K/4EBP1 pathway. The cell proliferation results show that the stimulatory function of METTL3 is lost after rapamycin treatment. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Retinoblastoma | ICD-11: 2D02.2 | ||
Pathway Response | PI3K-Akt signaling pathway | hsa04151 | ||
mTOR signaling pathway | hsa04150 | |||
Cell Process | Cell proliferation | |||
Cell migration | ||||
Cell invasion | ||||
Cell apoptosis | ||||
In-vitro Model | WERI-Rb-1 | Retinoblastoma | Homo sapiens | CVCL_1792 |
Y-79 | Retinoblastoma | Homo sapiens | CVCL_1893 | |
In-vivo Model | To establish a subcutaneous tumour model in nude mice, 2 × 107 Y79 cells (METTL3 knockdown group: shNC, shRNA1 and shRNA2; METTL3 up-regulated group: NC and METLL3) were resuspended in 1 mL of pre-cooled PBS, and 200 uL of the cell suspension was injected subcutaneously into the left side of the armpit to investigate tumour growth (4 × 106 per mouse). | |||
Experiment 4 Reporting the m6A Methylation Regulator of This Target Gene | [4] | |||
Response Summary | The contribution of METTL3-mediated m6A modification of Ddit4 mRNA to macrophage metabolic reprogramming in non-alcoholic fatty liver disease and obesity. In METTL3-deficient macrophages, there is a significant downregulation of Serine/threonine-protein kinase mTOR (MTOR) and nuclear factor Kappa-B (NF-Kappa-B) pathway activity in response to cellular stress and cytokine stimulation, which can be restored by knockdown of DDIT4. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Non-alcoholic fatty liver disease | ICD-11: DB92 | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
HIF-1 signaling pathway | hsa04066 | |||
In-vivo Model | The 8-10 weeks old mice were fed either a high fat diet or HF-CDAA , ad lib for 6-12 weeks. Chow diet was used as control for HFD.The mouse liver was perfused with PBS through portal vein, and liver tissue was cut into small pieces by a scissor. The single cell was made using syringe plunger to mull the tissue, and passed through a 40 uM cell strainer. | |||
YTH domain-containing family protein 1 (YTHDF1) [READER]
Representative RIP-seq result supporting the interaction between MTOR and the regulator | ||
Cell Line | Hela | Homo sapiens |
Regulation | logFC: 1.73E+00 | GSE63591 |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [5] | |||
Response Summary | YTHDF1 contributes to the progression of HCC by activating PI3K/AKT/Serine/threonine-protein kinase mTOR (MTOR) signaling pathway and inducing EMT. | |||
Target Regulation | Down regulation | |||
Responsed Disease | Hepatocellular carcinoma | ICD-11: 2C12.02 | ||
Pathway Response | PI3K-Akt signaling pathway | hsa04151), mTOR signaling pathway | ||
Cell Process | Epithelial-mesenchymal transition | |||
Cell migration | ||||
Cell invasion | ||||
Cell proliferation | ||||
In-vitro Model | SNU-398 | Adult hepatocellular carcinoma | Homo sapiens | CVCL_0077 |
SK-HEP-1 | Liver and intrahepatic bile duct epithelial neoplasm | Homo sapiens | CVCL_0525 | |
PLC/PRF/5 | Adult hepatocellular carcinoma | Homo sapiens | CVCL_0485 | |
L-02 | Endocervical adenocarcinoma | Homo sapiens | CVCL_6926 | |
Huh-7 | Adult hepatocellular carcinoma | Homo sapiens | CVCL_0336 | |
Hep-G2 | Hepatoblastoma | Homo sapiens | CVCL_0027 | |
Hep 3B2.1-7 | Childhood hepatocellular carcinoma | Homo sapiens | CVCL_0326 | |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
HCCLM3 | Adult hepatocellular carcinoma | Homo sapiens | CVCL_6832 | |
In-vivo Model | Ten four-week-old BALB/c male nude mice (GemPharmatech, Jiangsu, China) were subcutaneously injected with control Huh7 cells 2 × 106 (left-back) and stable knockdown of YTHDF1 Huh7 cells 2 × 106 (right-back). These cells were respectively premixed with 50 ul Matrigel (Corning, 354,234) in 100 ul PBS. | |||
Fat mass and obesity-associated protein (FTO) [ERASER]
In total 4 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [6] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. ATF4 transcriptionally upregulated DDIT4 to suppress Serine/threonine-protein kinase mTOR (MTOR), which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Responsed Drug | Asparagine inhibitor | Approved | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Autophagy | hsa04140 | |||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene | [6] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. ATF4 transcriptionally upregulated DDIT4 to suppress Serine/threonine-protein kinase mTOR (MTOR), which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Responsed Drug | Chloroquine | Approved | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Autophagy | hsa04140 | |||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 3 Reporting the m6A Methylation Regulator of This Target Gene | [6] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Serine/threonine-protein kinase mTOR (MTOR) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Responsed Drug | Meclofenamate sodium | Approved | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Autophagy | hsa04140 | |||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 4 Reporting the m6A Methylation Regulator of This Target Gene | [6] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Serine/threonine-protein kinase mTOR (MTOR) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Responsed Drug | CB-839 | Phase 2 | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Autophagy | hsa04140 | |||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Methyltransferase-like 14 (METTL14) [WRITER]
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [7] | |||
Response Summary | The m6A modification level was decreased in GC and METTL14 was a key regulator resulting in m6A disorder in GC. METTL14 overexpression suppressed GC cell proliferation and aggression by deactivating the PI3K/AKT/Serine/threonine-protein kinase mTOR (MTOR) pathway and the EMT pathway, respectively. | |||
Target Regulation | Down regulation | |||
Responsed Disease | Gastric cancer | ICD-11: 2B72 | ||
Pathway Response | PI3K-Akt signaling pathway | hsa04151 | ||
mTOR signaling pathway | hsa04150 | |||
In-vitro Model | SGC-7901 | Gastric carcinoma | Homo sapiens | CVCL_0520 |
MGC-803 | Gastric mucinous adenocarcinoma | Homo sapiens | CVCL_5334 | |
GES-1 | Normal | Homo sapiens | CVCL_EQ22 | |
YTH domain-containing family protein 2 (YTHDF2) [READER]
In total 4 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [6] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. ATF4 transcriptionally upregulated DDIT4 to suppress Serine/threonine-protein kinase mTOR (MTOR), which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Responsed Drug | Asparagine inhibitor | Approved | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Autophagy | hsa04140 | |||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene | [6] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Serine/threonine-protein kinase mTOR (MTOR) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Responsed Drug | Chloroquine | Approved | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Autophagy | hsa04140 | |||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 3 Reporting the m6A Methylation Regulator of This Target Gene | [6] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Serine/threonine-protein kinase mTOR (MTOR) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Responsed Drug | Meclofenamate sodium | Approved | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Autophagy | hsa04140 | |||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 4 Reporting the m6A Methylation Regulator of This Target Gene | [6] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. ATF4 transcriptionally upregulated DDIT4 to suppress Serine/threonine-protein kinase mTOR (MTOR), which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Responsed Drug | CB-839 | Phase 2 | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Autophagy | hsa04140 | |||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Gastric cancer [ICD-11: 2B72]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [7] | |||
Response Summary | The m6A modification level was decreased in GC and METTL14 was a key regulator resulting in m6A disorder in GC. METTL14 overexpression suppressed GC cell proliferation and aggression by deactivating the PI3K/AKT/Serine/threonine-protein kinase mTOR (MTOR) pathway and the EMT pathway, respectively. | |||
Responsed Disease | Gastric cancer [ICD-11: 2B72] | |||
Target Regulator | Methyltransferase-like 14 (METTL14) | WRITER | ||
Target Regulation | Down regulation | |||
Pathway Response | PI3K-Akt signaling pathway | hsa04151 | ||
mTOR signaling pathway | hsa04150 | |||
In-vitro Model | SGC-7901 | Gastric carcinoma | Homo sapiens | CVCL_0520 |
MGC-803 | Gastric mucinous adenocarcinoma | Homo sapiens | CVCL_5334 | |
GES-1 | Normal | Homo sapiens | CVCL_EQ22 | |
Colorectal cancer [ICD-11: 2B91]
In total 5 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [] | |||
Response Summary | WM_Score correlated highly with the regulation of transcription and post-transcriptional events contributing to the development of colorectal cancer. In response to anti-cancer drugs, WM_Score highly negatively correlated (drug sensitive) with drugs which targeted oncogenic related pathways, such as MAPK, EGFR, and Serine/threonine-protein kinase mTOR (MTOR) signaling pathways, positively correlated (drug resistance) with drugs which targeted in apoptosis and cell cycle. Importantly, the WM_Score was associated with the therapeutic efficacy of PD-L1 blockade, suggesting that the development of potential drugs targeting these "writers" to aid the clinical benefits of immunotherapy. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
VEGF signaling pathway | hsa04370 | |||
mTOR signaling pathway | hsa04150 | |||
PD-L1 expression and PD-1 checkpoint pathway in cancer | hsa05235 | |||
Cell Process | Cell apoptosis | |||
Experiment 2 Reporting the m6A-centered Disease Response | [6] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. ATF4 transcriptionally upregulated DDIT4 to suppress Serine/threonine-protein kinase mTOR (MTOR), which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Responsed Drug | Asparagine inhibitor | Approved | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Autophagy | hsa04140 | |||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 3 Reporting the m6A-centered Disease Response | [6] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. ATF4 transcriptionally upregulated DDIT4 to suppress Serine/threonine-protein kinase mTOR (MTOR), which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Responsed Drug | Chloroquine | Approved | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Autophagy | hsa04140 | |||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 4 Reporting the m6A-centered Disease Response | [6] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Serine/threonine-protein kinase mTOR (MTOR) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Responsed Drug | Meclofenamate sodium | Approved | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Autophagy | hsa04140 | |||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 5 Reporting the m6A-centered Disease Response | [6] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Serine/threonine-protein kinase mTOR (MTOR) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Responsed Drug | CB-839 | Phase 2 | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Autophagy | hsa04140 | |||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Gastrointestinal cancer [ICD-11: 2C11]
Liver cancer [ICD-11: 2C12]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [5] | |||
Response Summary | YTHDF1 contributes to the progression of HCC by activating PI3K/AKT/Serine/threonine-protein kinase mTOR (MTOR) signaling pathway and inducing EMT. | |||
Responsed Disease | Hepatocellular carcinoma [ICD-11: 2C12.02] | |||
Target Regulator | YTH domain-containing family protein 1 (YTHDF1) | READER | ||
Target Regulation | Down regulation | |||
Pathway Response | PI3K-Akt signaling pathway | hsa04151), mTOR signaling pathway | ||
Cell Process | Epithelial-mesenchymal transition | |||
Cell migration | ||||
Cell invasion | ||||
Cell proliferation | ||||
In-vitro Model | SNU-398 | Adult hepatocellular carcinoma | Homo sapiens | CVCL_0077 |
SK-HEP-1 | Liver and intrahepatic bile duct epithelial neoplasm | Homo sapiens | CVCL_0525 | |
PLC/PRF/5 | Adult hepatocellular carcinoma | Homo sapiens | CVCL_0485 | |
L-02 | Endocervical adenocarcinoma | Homo sapiens | CVCL_6926 | |
Huh-7 | Adult hepatocellular carcinoma | Homo sapiens | CVCL_0336 | |
Hep-G2 | Hepatoblastoma | Homo sapiens | CVCL_0027 | |
Hep 3B2.1-7 | Childhood hepatocellular carcinoma | Homo sapiens | CVCL_0326 | |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
HCCLM3 | Adult hepatocellular carcinoma | Homo sapiens | CVCL_6832 | |
In-vivo Model | Ten four-week-old BALB/c male nude mice (GemPharmatech, Jiangsu, China) were subcutaneously injected with control Huh7 cells 2 × 106 (left-back) and stable knockdown of YTHDF1 Huh7 cells 2 × 106 (right-back). These cells were respectively premixed with 50 ul Matrigel (Corning, 354,234) in 100 ul PBS. | |||
Lung cancer [ICD-11: 2C25]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | METTL3-mediated m6 A methylation promotes lung cancer progression via activating PI3K/AKT/Serine/threonine-protein kinase mTOR (MTOR) pathway. | |||
Responsed Disease | Lung cancer [ICD-11: 2C25] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
PI3K-Akt signaling pathway | hsa04151 | |||
In-vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens | CVCL_0023 |
In-vivo Model | 5 × 106 A549 cells overexpressing METTL3 (Lv-METTL3) or control (Lv-Ctrl) were suspended in 100?uL phosphate-buffered saline (PBS), and were subcutaneously injected into mouse lower right flank. Drug treatment started in the Lv-METTL3 group when the tumour volume reached around 100 mm3. Mice were randomly divided into three groups to receive vehicle, GSK2536771 (30 mg/kg) or rapamycin (1 mg/kg). Drugs were administrated daily through intraperitoneal injection for 18 days. Treatment conditions were chosen as previously reported. | |||
Renal cell carcinoma [ICD-11: 2C90]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [2] | |||
Response Summary | Knockdown of METTL3 could obviously promote cell proliferation, migration and invasion function, and induce G0/G1 arrest,METTL3 acts as a novel marker for tumorigenesis, development and survival of RCC. Knockdown of METTL3 promoted changes in pI3K/AKT/Serine/threonine-protein kinase mTOR (MTOR) markers' expression with a gain in p-PI3k, p-AKT, p-mTOR and p-p70, and a loss of p-4EBP1. | |||
Responsed Disease | Renal cell carcinoma [ICD-11: 2C90] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Down regulation | |||
Cell Process | Epithelial-to-mesenchymal transition | |||
Arrest cell cycle at G0/G1 phase | ||||
In-vitro Model | ACHN | Papillary renal cell carcinoma | Homo sapiens | CVCL_1067 |
Caki-1 | Clear cell renal cell carcinoma | Homo sapiens | CVCL_0234 | |
Caki-2 | Papillary renal cell carcinoma | Homo sapiens | CVCL_0235 | |
HK2 | Normal | Acipenser baerii | CVCL_YE28 | |
In-vivo Model | Cells (5×106 cells in 200 uL) were suspended with 100 uL PBS and 100 uL Matrigel Matrix, and injected subcutaneously into the left armpit of each mouse. | |||
Retina cancer [ICD-11: 2D02]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [3] | |||
Response Summary | METTL3 promotes the progression of retinoblastoma through PI3K/AKT/Serine/threonine-protein kinase mTOR (MTOR) pathways in vitro and in vivo. METTL3 has an impact on the PI3K-AKT-mTOR-P70S6K/4EBP1 pathway. The cell proliferation results show that the stimulatory function of METTL3 is lost after rapamycin treatment. | |||
Responsed Disease | Retinoblastoma [ICD-11: 2D02.2] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | PI3K-Akt signaling pathway | hsa04151 | ||
mTOR signaling pathway | hsa04150 | |||
Cell Process | Cell proliferation | |||
Cell migration | ||||
Cell invasion | ||||
Cell apoptosis | ||||
In-vitro Model | WERI-Rb-1 | Retinoblastoma | Homo sapiens | CVCL_1792 |
Y-79 | Retinoblastoma | Homo sapiens | CVCL_1893 | |
In-vivo Model | To establish a subcutaneous tumour model in nude mice, 2 × 107 Y79 cells (METTL3 knockdown group: shNC, shRNA1 and shRNA2; METTL3 up-regulated group: NC and METLL3) were resuspended in 1 mL of pre-cooled PBS, and 200 uL of the cell suspension was injected subcutaneously into the left side of the armpit to investigate tumour growth (4 × 106 per mouse). | |||
Non-alcoholic fatty liver disease [ICD-11: DB92]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [4] | |||
Response Summary | The contribution of METTL3-mediated m6A modification of Ddit4 mRNA to macrophage metabolic reprogramming in non-alcoholic fatty liver disease and obesity. In METTL3-deficient macrophages, there is a significant downregulation of Serine/threonine-protein kinase mTOR (MTOR) and nuclear factor Kappa-B (NF-Kappa-B) pathway activity in response to cellular stress and cytokine stimulation, which can be restored by knockdown of DDIT4. | |||
Responsed Disease | Non-alcoholic fatty liver disease [ICD-11: DB92] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
HIF-1 signaling pathway | hsa04066 | |||
In-vivo Model | The 8-10 weeks old mice were fed either a high fat diet or HF-CDAA , ad lib for 6-12 weeks. Chow diet was used as control for HFD.The mouse liver was perfused with PBS through portal vein, and liver tissue was cut into small pieces by a scissor. The single cell was made using syringe plunger to mull the tissue, and passed through a 40 uM cell strainer. | |||
Asparagine inhibitor
[Approved]
In total 2 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [6] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. ATF4 transcriptionally upregulated DDIT4 to suppress Serine/threonine-protein kinase mTOR (MTOR), which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Autophagy | hsa04140 | |||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 2 Reporting the m6A-centered Drug Response | [6] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. ATF4 transcriptionally upregulated DDIT4 to suppress Serine/threonine-protein kinase mTOR (MTOR), which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Up regulation | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Autophagy | hsa04140 | |||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Chloroquine
[Approved]
In total 2 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [6] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. ATF4 transcriptionally upregulated DDIT4 to suppress Serine/threonine-protein kinase mTOR (MTOR), which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Autophagy | hsa04140 | |||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 2 Reporting the m6A-centered Drug Response | [6] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Serine/threonine-protein kinase mTOR (MTOR) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Up regulation | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Autophagy | hsa04140 | |||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Meclofenamate sodium
[Approved]
In total 2 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [6] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Serine/threonine-protein kinase mTOR (MTOR) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Autophagy | hsa04140 | |||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 2 Reporting the m6A-centered Drug Response | [6] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Serine/threonine-protein kinase mTOR (MTOR) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Up regulation | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Autophagy | hsa04140 | |||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Rapamycin
[Approved]
In total 2 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [6] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Serine/threonine-protein kinase mTOR (MTOR) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Autophagy | hsa04140 | |||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 2 Reporting the m6A-centered Drug Response | [6] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Serine/threonine-protein kinase mTOR (MTOR) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Up regulation | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Autophagy | hsa04140 | |||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
CB-839
[Phase 2]
In total 2 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [6] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Serine/threonine-protein kinase mTOR (MTOR) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Autophagy | hsa04140 | |||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 2 Reporting the m6A-centered Drug Response | [6] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. ATF4 transcriptionally upregulated DDIT4 to suppress Serine/threonine-protein kinase mTOR (MTOR), which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Up regulation | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Autophagy | hsa04140 | |||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
GLS-IN-968
[Investigative]
In total 2 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [6] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. ATF4 transcriptionally upregulated DDIT4 to suppress Serine/threonine-protein kinase mTOR (MTOR), which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Autophagy | hsa04140 | |||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 2 Reporting the m6A-centered Drug Response | [6] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. ATF4 transcriptionally upregulated DDIT4 to suppress Serine/threonine-protein kinase mTOR (MTOR), which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Up regulation | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Autophagy | hsa04140 | |||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
References